Melittin engineered peptide and application thereof
By structurally modifying natural melittin peptides, a modified melittin peptide (Melittin-m1-5) was obtained, which solved the cytotoxicity and hemolytic side effects of natural melittin peptides, and realized anti-inflammatory drugs and topical preparations with higher safety and wider application range.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- NANHUA UNIV
- Filing Date
- 2026-06-03
- Publication Date
- 2026-07-17
AI Technical Summary
Existing natural bee venom peptides exhibit strong cytotoxicity and hemolytic side effects when exerting anti-inflammatory activity, and their low stability limits their application in pharmaceuticals and related products.
By structurally modifying natural bee venom peptides, a modified bee venom peptide (Melittin-m1-5) was obtained. Its amino acid sequence is Arg Ile Arg Arg Trp Leu Lys Arg Leu Arg Thr Arg Leu Ala Arg Leu Ile Ser Arg, with a molecular weight of 2520 Da. It significantly reduces cytotoxicity and hemolytic side effects while retaining anti-inflammatory activity.
The modified melitrix peptide significantly reduces cytotoxicity and hemolytic activity, improves safety, and can effectively inhibit the expression of inflammatory factors, making it suitable for the preparation of anti-inflammatory drugs and topical formulations with low hemolytic risk.
Smart Images
Figure CN122404522A_ABST